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ABSTRACT 
HANNAH LYNN CARSON: The Histone Deacetylase Inhibitor Largazole: A 
Potential Chemotherapeutic Agent 
(Under the advisement of Drs. Yu-Dong Zhou and Dale Nagle) 
 
 
 Histone deacetylase enzymes are known for their inherent activity as 
epigenetic modifiers. Although, they have become recognized for their role in cancer 
progression and other diseases. But also, histone deacetylases have other non-histone 
targets, for example, microtubules, which play important roles in cancer metastasis, 
apoptosis, and replication. With histone deacetylase inhibitors (HDACi), our research 
explored HDACi effects on breast cancer cell lines. The overall goal was to 
understand the potential of largazole, a class one histone deacetylase inhibitor on 
breast cancer cell lines. The research consisted of two parts: sulforhodamine B (SRB) 
viability assays under hypoxic and normoxic conditions. The specific cell lines that 
were used were MCF-7, MCF-7 BoM, MDA-MB-231, and MDA-MB-231 BoM. The 
results of the experiments showed that histone deacetylase inhibitors, specifically 
Largazole is a useful chemotherapeutic agent against breast cancer. Also, Hypoxic 
conditions in combination with cycloheximide did lead to lower cell proliferation. 
The MCF-7 and MDA-231 had greater inhibition in normoxic condition. The BoM 
cell lines had greater inhibition in both conditions. And as expected the triple-
negative did require a greater largazole concentration for effect to take place in the 
hypoxic conditions.  The extremely aggressive cancer cell-line MDA-MB-231 gave 
the most conclusive results.  
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INTRODUCTION: BREAST CANCER  
 
Through the years I have known many women who have triumphed through 
the diagnosis of breast cancer. This disease is the most common cancer and primary 
cause of cancer related death in females (Akram 1). Meaning that about 12% of 
women in the U.S. will develop breast cancer in their lifetime (breastcancer.org). 
This year alone, roughly 42,000 women are expected to die from breast cancer 
(breastcancer.org). These startling facts are what push researchers and medical 
professionals to work for a cure to ensure a healthier future for women. 
When a student is learning about cancer the first piece of information that is 
taught is that there are eight remarkable  Hallmarks of cancer, they are: “sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, reprogramming energy metabolism, 
evading immune response, and activating invasion and metastasis.”(Hanahan 1). 
Recognition of these cancer hallmarks are what lead researchers to understand more 
about cancer and potential ways to cure this disease. Although, research is fascinating 
and continues to make great discoveries every day. Women can take part in 
preventative medicine to reduce the risks of breast cancer. John Hopkins lists the 
following as preventative healthcare: “take care of yourself emotionally, physically, 
reduce stress, eat healthy, and see the doctor for regular health screenings” (John 
Hopkins, 1). Although these were listed for women to reduce the risk of breast cancer, 
this advice is useful for all cancer prevention. 
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The bad news is there is only so much that women can do, there are also non-
modifiable factors, those cannot be prevented; such as age, race, mutated genes, 
family and personal history, late menopause, and even height are all associated with 
a predisposition to breast cancer. According to the Center of Disease Control and 
Prevention, 1 out of 10 women are diagnosed with some form of breast cancer under 
the age of 45 due to the BRCA1 and BRCA2 mutation, descent of the Ashkenazi 
Jewish heritage, exposure to radiation, or a close relative diagnosed with breast 
cancer or ovarian cancer before the age of 45 (CDC 1). Another non-modifiable 
factor is breast density, related to rather a woman's breast being more fibrous or 
glanderous than fat, leading to greater density in the breast causing it to be more 
difficult to locate tumors using a mammogram. 
In general, breast cancer is generally described at ductal or lobular, other 
forms exist as well but are less common such as tubular, mucinous, medullary, and 
papillary. Lobular carcinomas begin in the milk producing glands, whereas; ductal is 
in cells of the milk duct (MD Anderson 1). Each tumor is different and unique, and 
the prognosis is dependent on the type of tumor. For example, those diagnosed with 
mucinous (colloid) carcinoma tend to have a better prognosis than those diagnosed 
with an invasive ductal carcinoma (Susan G. Komen 1). There are also three types of 
molecular receptor-based classifications of breast cancers, these include HER2, ER, 
and triple-negative (MD Anderson 1). The HER2 (Human Epidermal Growth Factor 
receptor 2) is positive, then the cancer will be reluctant to respond to hormone 
therapies, because the receptor works specifically to cause growth of cancer cells. 
The ER-positive breast cancer (Estrogen Receptor) is another possible source of 
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promoting cancer cell growth. Triple-negative breast cancer is known to spread much 
faster because it lacks ER, PR (Progesterone Receptors), and does not overexpress 
HER2 growth receptors, anti-hormone therapies are not useful (cancer.org 1). As 
seen through all the breast cancer variations and the risk of women, the goal of 
researchers and doctors is to find the best course of action for each individual patient. 
Cancer results from a combination of mutations. The genes in our body are carried 
in the DNA molecules, and if a mutation occurs it can change the amount or activities 
carried out by particular proteins (Weinburg 1). Specifically, these cancer related 
genes are called proto-oncogenes and modifications of tumor suppressor genes, 
which lead to uncontrolled cell proliferation. Many proto-oncogenes relay growth 
signals from the outside of the cell to the deep interior, when the mutation occurs the 
growth signaling pathway remains continuously active when it should be silent 
(Weinberg 2). These growth factors promote cancer metastasis. For example, 
approximately one-third of women who are sentinel lymph node negative at the time 
of surgical resection of the primary breast tumor will subsequently develop clinically 
detectable secondary tumors (Hunter 1). Simply put with metastatic breast cancer 
there is risk that removal of the tumor could lead to an increase in the circulation of 
cancer cells in the body leading to cancer at a distal sight. Metastatic breast cancer is 
stage IV, although not always caused by surgery the cancer may just progress to the 
point of spreading to local or distal sights. With experiments and countless hours in 
the lab Drs. Zhou and Nagle allowed me and my lab partner Hannah McCowan to 
study possible ways to stop metastatic breast cancer. The use of histone deacetylase 
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inhibitors, specifically the marine natural product largazole, could be a potential 
answer to prevent malignant breast cancer.  
 
Histone Deacetylase Inhibitors 
The human genome contains approximately 3.2×109 nucleotides—is 
distributed over 24 different chromosomes (Johnson 1). The chromosome contains 
long, linear DNA associated with proteins and contains those that are used in gene 
expression and DNA replication and repair (Johnson 1). Histone modifications are 
what allow gene expression, for example histone acetylation allows for higher 
expression (Harb 2). “Histone acetylation status is regulated by two groups of enzymes 
exerting opposite effects, histone acetyltransferases (HATs) and histone deacetylases 
(HDACs).” (Harb 3).  
The definition of an inhibitor is an agent that slows or interferes with a 
chemical action (Merriam webster). These inhibitors can interfere with epigenetic 
enzymes created through mutations caused by cancer in the body. These epigenetic 
enzymes cause modifications in the methylation and histone modifications and cause 
extensive changes without altering the DNA sequence (Han 1). Specifically, “Histone 
acetylation is an important epigenetic modification that mainly occurs in the N-
terminal region of the histone tail.” (Han 5). The acetylation acts to weaken the 
binding between DNA and histones, ultimately leading to relaxed chromatin causing 
increased gene expression (Han 5).The acetylation occurs and cause neutralization of 
the positive charges by binding with lysine residues, this process can decrease the 
affinity for DNA. Because of this, researchers know that “histone acetylation alters 
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nucleosomal conformation” leading to increased availability of transcription 
regulatory proteins (Struhl 1). This could cause overexpression and lead to cancer. 
“Mutations in genes encoding HDACs are associated with the progression of tumors, 
owing to the abnormal transcription of key genes that regulate important cellular 
functions such as cell proliferation, cell cycle regulation and apoptosis,” (Han 5) and 
certain histone deacetylase (HDAC) inhibitors can be used as anticancer agents. 
These are important agents because the histone acetylases are used in determination 
of gene expression (West 1). Whereas, the deacetylase is useful in the regulation 
process as it removes the acetyl group from the histone (West 1). The inhibition of 
HDAC1 and HDAC2 can cause hypersensitivity in cancer cells. But in the past, 
histone deacetylase inhibitors have only been useful on nontumor forming cancers. 
Specifically, blood cancers like leukemia and T-cell subcutaneous lymphoma.   
Largazole 
The natural product largazole is a cyclic depsipeptide, from marine Symploca 
sp. cyanobacteria with novel chemical scaffold that potently inhibits class I histone 
deacetylases. (Hong 1). The mechanism of action of largazole is similar to drugs like 
vorinostat (Zolinza®) and romidepsin (Istodax®), Vorinostat is a drug that inhibits class 
I, II, and IV HDAC molecules and romidepsin inhibits class I HDAC molecules 
(Hong1). The Symploca sp. extract was originally collected in Key Largo, Florida; 
where it was found to have remarkable antiproliferative activity (Hong 2).The name 
largazole was due to the occurrence in Key Largo and the “azole” because of the one 
thiozole linearly fused to a 4-methylthiazoline (Hong 2). Largazole contains only one 
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non modified standard amino acid and three stereogenic centers. Its 3-hydroxy-7-
mercapto-hept-4-enoic acid is unique among marine natural products. 
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Figure 1. Largazole Structure 
 
The cytotoxicity of the drug was tested on different tumor cell lines (i.e., colorectal 
carcinoma, breast cancer, neuroblastoma, and osteosarcoma) and was shown to inhibit their 
growth at nanomolar concentrations. Remarkably, non-transformed epithelial cells and 
fibroblasts were less sensitive to its effects (Hong2-3). Mechanism of action studies indicated 
that the antiproliferative activity of largazole results from the inhibition of HDAC enzymes 
(Hong 3). Because of the functionality of the thioester suggested that through hydrolysis 
largazole could be converted into a HDAC inhibitor (Hong 3). “Largazole activation appears 
to be induced through a general protein-assisted mechanism, which may explain why 
largazole itself displayed apparent activity in the in vitro enzymatic assay with recombinant 
HDAC1 enzyme, although with about 10-fold lower potency.” (Hong 3). The thiol in 
largazole presents itself to be stable in freeform and reversible adduct, could result in 
hijacking of proteins for delivery to the target site. But denatured proteins did not form 
adducts with largazole thiol. In addition, it has been found that largazole lacks acute toxicity, 
resulting in largazole being a potentially safe anticancer HDAC inhibitor (Hong 8).  
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Figure 2: Mechanism of action. A) Modes of action of largazole and FK228 to 
liberate potent HDAC inhibitors. B) Molecular docking of largazole thiol into an HDAC1 
homology model. PG = Protecting group.  
 
Histone Deacetylase Inhibitor Experiment 
 
The research for this project began in the Fall of 2018 under the guidance of Drs. 
Zhou and Nagle. The first part of the project began with a cancer research course to learn the 
background of cancer and specifics of breast cancer. The next semester the time was spent 
in the lab learning important laboratory procedures and techniques to sufficiently carry out 
the experiments. Beginning in Fall of 2019 the official research project began, the team 
developed a project and the actual experiments were put into place. The overall goal was to 
discover the effects of largazole in varying concentrations, on breast cancer cells. Therefore, 
the HDACi(s), specifically HDAC I inhibitors were studied. The general hypothesis of this 
experiment was to understand the effects of HDACi(s) on breast cancer cells. 
 
MATERIALS AND METHODS 
Background Research 
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With the decision to pursue the use of HDAC(i)’s as a form of cancer treatment, the real 
research began. This process began with mini lectures each time learning more and more of what 
each experiment would entail. Afterwards we began to gather what was needed to conduct the 
experiments. Dr. Zhou specifically mentioned studying largazole and its effects on breast cancer. 
The overall research design was to discover the effects of differing concentrations of largazole 
on four different cancer cell lines. Largazole was obtained from Professor Luesch at the 
University of Florida College of Pharmacy. The human cancer cell lines were the MCF-7 (ductal 
carcinoma), MDA-MB-231 (breast adenocarcinoma), and subtypes MDA-MB-231 BoM and 
MCF-7 BoM, these were all from ATCC. The MDA-MB-231 was from a 51-year-old Caucasian 
woman with triple negative breast cancer from a pleural effusion. Sadly, this is an aggressive 
tumor with a poor prognosis. The MCF-7 was from a 69-year-old Caucasian woman with triple-
negative breast cancer, the unique aspect about this tumor is its ER-positive, meaning it grows 
with response to the hormone estrogen. The MCF-7 BoM cell line was from a bone secondary 
metastasis acquired from Dr. J Massagué’s lab at the Sloan Kettering Cancer Center. And our 
research group specifically received the cells from Dr. Konosuke Watabe at Wake Forest 
University.  
 
 
 
 
Sulforhodamine B (SRB) Viability Assay 
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The SRB Viability Assay was developed to measure the drug-induced cytotoxicity 
(voigt 1).  The method is useful in discovering the cell density determination depending on 
the amount of cellular protein content (Viachi 1). This is a useful method because it can test 
large samples in a matter of days and the materials used are inexpensive. Therefore, SRB is 
a useful and cost-effective method of screening. For this experiment to take place it is broken 
up into four main steps: preparation of treatment, incubation of the cells with a treatment, fix 
the cells and add the SRB staining, and measure the absorbance (Orellana 1). Beginning the 
experiment, the cell cultures were trypsinized with 1 mL (Trypsin).  The cells were then 
washed with 10 mL of 10% fetal calf serum (FCS) media. Then the 100 μL of solution and 
10% FCS were seeded to each well on a 96-well plate, at varying concentrations ranging 
from 30,000 cells/mL, 20,000 cells/mL, and 15,000 cells/mL. The cells were then cultured 
at 37℃ with 95% air and 5% CO2 creating a humid environment. The 96-well plates were 
then infused with the chemotherapeutic drug, largazole which was prepared by serial 
dilutions. The cells were then incubated for 48 hours and afterwards a 100 μL of media was 
removed for the cell wells. A cell count was then performed to ensure that cells were seeded. 
And the process of cell fixation began by adding 100 μL of 20% trichloroacetic acid (TCA) 
and 1% phosphate-buffered saline (PBS) solution into each of the wells. The PBS that was 
available was 10% so it was diluted with autoclaved water. The plates were then refrigerated 
at 4℃ for an hour. After the removal of the plates from the refrigerator the plates were then 
washed down with tap water from the sink four separate times. After the wells in the plates 
were dry, the wells were then stained with 100 μL of 4% SRB containing 1% Acetic acid 
and the plates sat at room temperature with the stain for a total of 10 minutes. Afterwards 
each well was washed three times with 1% acetic acid and then left to dry. A 100 μL of 10% 
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Tris buffer was added to the stained wells and were lightly shaken for 10 minutes on the 
microplate genie. The plates were then read by the SpectraFlour plus machine and Magellen 
software at the absorbance range of 490 nm to 620 nm. Overall, the sulforhodamine B dye 
is what binds to the proteins of the cell specifically the basic amino acids, which allows for 
the calculation of the inhibition value using the Magellen software. This inhibition value can 
be calculated by using the total protein mass per wall (indicated by the SRB dye) which is 
causally related to the cell density of that specific cell.  
 
Hypoxic and Normoxic Experiments 
 
Hypoxic conditions are defined as cells, tissues, or organs that lack sufficient oxygen. 
Hypoxia can be caused by the presence of tumors in the body and the cells can learn to adapt 
to that environment. During hypoxia, hypoxia-inducible factor-1 (HIF-1) is activated to 
regulate various genes such as those involved in angiogenesis or oxygen transport. The 
stabilization of this transcription factor is a hallmark of hypoxia, therefore detecting elevated 
levels of HIF-1 is used to screen for tumors hypoxia. (Wu 1). Part of the experiment after the 
SRB Assay was performed, the research team decided to see the effects of hypoxia on the 
cells after treatment with largazole. This was accomplished by putting one set of plates in 
the Hypoxia chamber with a petri dish containing sterilized water, this allows for adequate 
humidification of the cells. The other set of cells were placed in normoxic conditions as a 
control. In the hypoxia chamber the conditions were set at 1% O2 gas mixture. In order to 
remove most of the oxygen from the chamber it was flushed by opening the gas tank. And 
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the gas flow was turned off and the chamber was closed completely. Following the de-gasing 
process the chamber was then returned to normal incubation. 
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Results and Discussion 
SRB Viability Assay 
 
The results of the sulforhodamine B viability assay show the percent inhibition of 
values of largazole tested on MCF-7, MCF-7 BoM, MDA-MB-231, and MDA-MB-231 BoM 
cell lines. One goal of the viability test was to determine the IC50 values (the half-maximal 
inhibitory concentration when measuring the potency of a substance in inhibition). Although 
the results provided inhibition, the IC50 value was not attained because more than 50% was 
inhibited. The figures below show the results of viability due to varying largazole 
concentrations depending on hypoxic and normoxic conditions. Also, bar graphs in comparing 
media control versus cycloheximide. My lab partner and I configured the data together and 
processed the graphs through graph pad. 
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Figure 3. The effect of largazole on MCF-7 cell proliferation/viability under 
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate. 
 
Figure 4. The effect of largazole on MCF-7 cell proliferation/viability under 
normoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
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Figure 5. The effect of largazole on MCF7-BoM cell proliferation/viability under 
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
 
 
Figure 6. The effect of largazole on MCF7-BoM cell proliferation/viability under 
normoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
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Figure 7. The effect of largazole on MDA-MB-231 cell proliferation/viability under 
hypoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
 
Figure 3. The effect of largazole on MDA-MB-231 cell proliferation/viability under 
normoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
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Figure 9. The effect of largazole on BoM cell proliferation/viability under normoxic 
conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
 
Figure 10. The effect of largazole on BoM cell proliferation/viability under 
normoxic conditions. Data shown are average +/- standard deviation of the mean from one 
experiment performed in triplicate 
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Figure 11. MCF-7 cell line effects on cell growth/viability under hypoxic/normoxic 
and the effects of cycloheximide.  
 
Figure 12. MCF7- BoM cell line effects on cell growth/viability under 
hypoxic/normoxic and the effects of cycloheximide  
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Figure 13. MDA-MB-231 cell line effects on cell growth/viability under 
hypoxic/normoxic and the effects of cycloheximide 
 
Figure 14. MDA-MB-231 BoM cell line effects on cell growth/viability under 
hypoxic/normoxic and the effects of cycloheximide.  
 
The first eight graphs in the figures above represent tumor cell viability in relation to 
hypoxic and normoxic controls and the effects of cycloheximide in comparison to media 
controls. In each graph it is evident that the hypoxic control leads to a smaller percent 
inhibition in comparison to normoxic conditions. Therefore, it can be said that hypoxia 
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conditions cause the cell lines to be less susceptible to cytotoxic effects of the drug largazole. 
As expected, the triple negative required a higher concentration of largazole in hypoxic 
conditions. Triple negative breast cancer is one of the most difficult to treat, therefore 
requiring a higher drug concentration. The hypoxic and normoxic conditions had the least 
effects on the MCF-7 and MDA-MB-231 BoM cell lines. It can be stated that the normoxic 
control does produce a higher percent inhibition overall. The MCF-7 BoM cell line provided 
drastic results between the hypoxic and normoxic conditions, further proving that normoxic 
conditions produce a much larger percent inhibition. The negative values are evidence of 
error for example improper serial dilutions.  For more reliable data all four cell lines should 
be further tested to attain IC50 values. 
An interesting data trend was provided by the last four figures. The media control 
was overall less effective than cycloheximide, a highly toxic fungicide. In each of the finding 
less cell proliferation was found in each cell line due to the use of 10 μM cycloheximide. 
Also, in the data shown above, the majority of the time the hypoxia condition leads to equal 
or lower cell proliferation in regard to media control and cycloheximide; with exception to 
the MCF-7 BoM, the media control hypoxic condition was higher than under normoxic 
conditions. Overall, the growth inhibition never reached complete inhibition and was most 
prominent at the highest concentrations of largazole.  
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Conclusion 
An overview of the analysis of the SRB viability assay and the hypoxia versus 
normoxia conditions of multiple different cell lines, our hypothesis largazole does have an 
impact on cell lines, as does hypoxic and normoxic conditions. The MCF-7 and MDA-231 
had greater inhibition in normoxic condition. The BoM cell lines had greater inhibition in 
both conditions. And as expected the triple-negative did require a greater largazole 
concentration for effect to take place in the hypoxic conditions.  The four cell lines, MCF-7, 
MCF 7 BoM, MDA-MB-231, and MDA-MB-231 BoM had variation in inhibitor effects in 
SRB viability assays. This is most likely due to human error, possibly not accurate dilutions. 
Therefore, further testing should be done. Also, more research should be conducted at higher 
concentrations to attain IC50 values of the marine natural product largazole. The use of 
cycloheximide did prove to be effective and the hypoxic conditions did lead to lower cell 
proliferation. In order, to improve the results more testing should be done at a higher 
cycloheximide concentration direct comparison of largazole and cycloheximide. 
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